Boston Scientific Co. (NYSE:BSX) Stock Position Raised by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd grew its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 4,292.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,676,847 shares of the medical equipment provider's stock after buying an additional 2,615,903 shares during the period. Boston Scientific accounts for approximately 1.1% of AustralianSuper Pty Ltd's holdings, making the stock its 21st biggest holding. AustralianSuper Pty Ltd owned approximately 0.18% of Boston Scientific worth $224,320,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Congress Asset Management Co. lifted its holdings in shares of Boston Scientific by 3.2% during the 3rd quarter. Congress Asset Management Co. now owns 1,718,654 shares of the medical equipment provider's stock valued at $144,023,000 after acquiring an additional 53,346 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. acquired a new position in shares of Boston Scientific during the 3rd quarter valued at $30,000. S.A. Mason LLC lifted its holdings in shares of Boston Scientific by 6.1% during the 3rd quarter. S.A. Mason LLC now owns 2,335 shares of the medical equipment provider's stock valued at $196,000 after acquiring an additional 135 shares in the last quarter. Oak Harvest Investment Services lifted its holdings in shares of Boston Scientific by 60.7% during the 3rd quarter. Oak Harvest Investment Services now owns 11,250 shares of the medical equipment provider's stock valued at $943,000 after acquiring an additional 4,250 shares in the last quarter. Finally, First Trust Direct Indexing L.P. lifted its holdings in shares of Boston Scientific by 18.6% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 54,308 shares of the medical equipment provider's stock valued at $4,551,000 after acquiring an additional 8,518 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the company's stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the sale, the executive vice president now directly owns 160,467 shares of the company's stock, valued at approximately $13,639,695. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the sale, the executive vice president now directly owns 160,467 shares of the company's stock, valued at $13,639,695. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael F. Mahoney sold 162,777 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the sale, the chief executive officer now directly owns 1,572,096 shares of the company's stock, valued at approximately $133,046,484.48. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 309,270 shares of company stock valued at $26,196,718. Company insiders own 0.50% of the company's stock.

Analyst Ratings Changes

BSX has been the topic of several recent research reports. Truist Financial lifted their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a report on Monday, October 14th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Boston Scientific from $73.00 to $78.00 and gave the stock a "hold" rating in a report on Thursday, July 25th. Royal Bank of Canada boosted their price objective on shares of Boston Scientific from $95.00 to $98.00 and gave the stock an "outperform" rating in a report on Thursday, October 24th. Sanford C. Bernstein boosted their price objective on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an "outperform" rating in a report on Thursday, October 24th. Finally, Raymond James boosted their price objective on shares of Boston Scientific from $91.00 to $94.00 and gave the stock a "strong-buy" rating in a report on Wednesday, September 4th. Three analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $93.39.

Boston Scientific Stock Performance

NYSE BSX traded up $0.03 on Thursday, hitting $84.02. The stock had a trading volume of 7,427,184 shares, compared to its average volume of 6,101,325. Boston Scientific Co. has a one year low of $50.26 and a one year high of $88.79. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. The stock has a market cap of $123.27 billion, a price-to-earnings ratio of 70.61, a P/E/G ratio of 2.87 and a beta of 0.80. The company's 50-day moving average is $83.82 and its two-hundred day moving average is $78.13.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping the consensus estimate of $0.59 by $0.04. The firm had revenue of $4.21 billion during the quarter, compared to analysts' expectations of $4.04 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. Boston Scientific's quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.50 EPS. On average, analysts expect that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.